ARYx discovers and develops novel drugs for large, chronic disease markets, unresolved by currently available therapies due to limitations in drug design and metabolism problems.

Read More

Gastrointestinal Therapy Has A New Name

Indicative of its progress towards Phase 3 clinical development, our gastrointestinal product candidate has been granted the name naronapride (ATI-7505).
Learn more

A Growing Clinical Stage Product Pipeline

We are developing a portfolio of novel, oral product candidates aimed at large, chronic markets. We currently have four product candidates in clinical development, three of which are in Phase 3 or are Phase 3 ready.
Learn more


RetroMetabolic Drug Design

We use proprietary technologies to design structurally unique and patentable molecules that retain the efficacy of proven therapies while eliminating specific adverse side effects associated with these therapies.
Learn more

 



built@zoomedia